188 related articles for article (PubMed ID: 15242681)
1. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease.
Hammerschmidt W; Sugden B
Trends Mol Med; 2004 Jul; 10(7):331-6. PubMed ID: 15242681
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
3. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Vockerodt M; Tesch H; Kube D
Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.
Grässer FA; Murray PG; Kremmer E; Klein K; Remberger K; Feiden W; Reynolds G; Niedobitek G; Young LS; Mueller-Lantzsch N
Blood; 1994 Dec; 84(11):3792-8. PubMed ID: 7949135
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
8. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
9. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination.
Walter J; Schirrmacher V; Mosier D
Int J Cancer; 1995 May; 61(3):363-9. PubMed ID: 7537255
[TBL] [Abstract][Full Text] [Related]
11. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
12. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.
Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
Curr Top Microbiol Immunol; 2001; 258():153-60. PubMed ID: 11443860
[No Abstract] [Full Text] [Related]
13. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of Epstein-Barr virus in different types of lymphoma.
Shaklawoon K; Altagazi N; Altorjman F; Alturki A; Eltaweel M; Alqawi O
Mol Biol Rep; 2020 Mar; 47(3):1803-1807. PubMed ID: 31993862
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines.
Touitou R; Arbach H; Cochet C; Feuillard J; Martin A; Raphaël M; Joab I
J Gen Virol; 2003 Apr; 84(Pt 4):949-957. PubMed ID: 12655096
[TBL] [Abstract][Full Text] [Related]
18. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
19. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
Kuljić-Kapulica N
Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
[TBL] [Abstract][Full Text] [Related]
20. Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.
Zebboudj A; Maroui MA; Dutrieux J; Touil-Boukoffa C; Bourouba M; Chelbi-Alix MK; Nisole S
Biochimie; 2014 Dec; 107 Pt B():247-56. PubMed ID: 25241256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
